-
CDC⁺ biobetter antibodies are cutting-edge therapeutic agents engineered to enhance complement-dependent cytotoxicity (CDC), a mechanism that plays a crucial role in the immune system’s ability to eliminate pathogens and diseased cells. By improving the efficiency of the CDC pathway, these biobetter antibodies offer greater potency and specificity in targeting diseased cells, particularly in the treatment of autoimmune disorders and cancers. The design of CDC⁺ biobetter antibodies involves modifications that increase their ability to recruit and activate the complement system, thereby amplifying the antibody’s overall cytotoxic effect. As a result, CDC⁺ biobetter antibodies hold significant promise for providing more effective treatments with potentially reduced side effects compared to conventional monoclonal antibodies.
-
Category
Research -
Created
Tuesday, 10 June 2025 -
Group admin
Gemini Smith
My Portfolio
Close X
Mentor Center